APT Pharmaceuticals, Inc.
http://www.aptbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From APT Pharmaceuticals, Inc.
Shionogi, Qpex Agree On Anti-Infective-Focused US R&D Site
Shionogi says first major US R&D site will enhance capabilities for both Shionogi and its 2023 acquisition Qpex, which prompted the Japanese firm to build on the San Diego company's close research collaborations with US government organizations.
Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive
The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Stoke’s Persistence Pays Off With Dravet Syndrome Therapy
Results showing a 74% reduction in seizures set up Stoke for a pivotal study and could make STK-001 the first disease-modifying agent for the condition.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice